The JAK2 rs12343867 CC genotype frequently occurs in patients with splanchnic venous thrombosis without the JAK2V617F mutation: A retrospective study

Journal of Thrombosis and Haemostasis

Volumn 8, Issue 2, 2010, Pages 413-416

  Colaizzo, D ^a   Tiscia, G L ^a   Bafunno, V ^b   Amitrano, L ^c   Vergura, P ^a   Grandone, E ^a   Guardascione, M A ^c   Margaglione, M ^b  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^b UNIVERSITY OF FOGGIA   (Italy)

^c CARDARELLI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; JANUS KINASE 2;

ADOLESCENT; ADULT; AGED; ALLELE; BUDD CHIARI SYNDROME; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; MESENTERIC VEIN THROMBOSIS; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SPLANCHNIC VEIN THROMBOSIS; THROMBOPHILIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; VEIN THROMBOSIS;

ADOLESCENT; ADULT; AGED; CHI-SQUARE DISTRIBUTION; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; JANUS KINASE 2; LOGISTIC MODELS; MALE; MIDDLE AGED; MUTATION; ODDS RATIO; PHENOTYPE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SPLANCHNIC CIRCULATION; VENOUS THROMBOSIS; YOUNG ADULT;

EID: 74749083459     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2009.03691.x     Document Type: Letter

References (9)

1. Chait Y, Condat B, Cazals-Hatem D, Rufat P, Atmani S, Chaoui D, Guilmin F, Kiladjian JJ, Plessier A, Denninger MH, Casadevall N, Valla D, Brière JB. Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosis. Br J Haematol 2005, 129:553-60.
2. Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med 2006, 355:2452-66.
3. Dentali F, Squizzato A, Brivio L, Appio L, Campiotti L, Crowther M, Grandi AM, Ageno W. JAK2V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis. Blood 2009, 113:5617-23.
4. Jones AV, Chase A, Silver RT, Oscier D, Zoi K, Wang YL, Cario H, Pahl HL, Collins A, Reiter A, Grand F, Cross NC. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet 2009, 4411:446-9.
5. Olcaydu D, Harutyunyan A, Jager R, Berg T, Gisslinger B, Pabinger I, Gisslinger H, Kralovics R. A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet 2009, 41:450-4.
6. Kilpivaara O, Mukherjee S, Schram AM, Wadleigh M, Mullally A, Ebert BL, Bass A, Marubayashi S, Heguy A, Garcia-Manero G, Kantarjian H, Offit K, Stone RM, Gilliland DG, Klein RJ, Levine RL. A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat Genet 2009, 41:455-9.
7. Pierre R, Imbert M, Thiele J, Vardiman JW, Brunning RD, Brunning G, Jaffe ES, Harris NL, Stein H, Vardiman JW. Pathology and genetics of tumors of haematopoietic and lymphoid tissues. The World Health Organization Classification of Tumors 2001, 32-44. In, eds, Lyon, IARC Press
8. Margaglione M, Brancaccio V, Giuliani N, D'Andrea G, Cappucci G, Iannaccone L, Vecchione G, Grandone E, Di Manno G. Increased risk of venous thrombosis in carriers of the prothrombin A20210 gene variant. Ann Intern Med 1998, 129:89-93.
9. Denninger MH, Chait Y, Casadevall N, Hillaire S, Guillin MC, Bezeaud A, Erlinger S, Briere J, Valla D. Cause of portal or hepatic vein thrombosis in adults: the role of multiple concurrent factors. Hepatology 2000, 31:587-91.